Dainippon Sumitomo Pharma Licenses Precursor of Norepinephrine to Chelsea Therapeutics International.Tokyo, Japan, June 5, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Dainippon Sumitomo Pharma has signed a licensing agreement with US pharmaceutical company Chelsea Therapeutics International. Under the agreement terms, Chelsea Therapeutics International will receive exclusive rights to develop and sell Dops, Dainippon Sumitomo Pharma's proprietary agent, worldwide except in Japan, China, South Korea and Taiwan. In Japan, Dops, which is a precursor of norepinephrine norepinephrine (nôr'ĕpīnĕf`rən), a neurotransmitter in the catecholamine family that mediates chemical communication in the sympathetic nervous system, a branch of the autonomic nervous system. , is currently available for the treatment of frozen gait and dizziness associated with Parkinson's disease Parkinson's disease or Parkinsonism, degenerative brain disorder first described by the English surgeon James Parkinson in 1817. When there is no known cause, the disease usually appears after age 40 and is referred to as Parkinson's disease. , and vertigo, dizziness and fatigue associated with orthostatic hypotension Orthostatic Hypotension Definition Orthostatic hypotension is an abnormal decrease in blood pressure when a person stands up. This may lead to fainting. in hemodialysis patients. Going forward, Chelsea Therapeutics International will develop the agent as an orphan drug for the treatment of orthostatic hypotension associated with autonomic disorder. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion